Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
WSD-0922 by Wayshine Biopharma for Non-Small Cell Lung Cancer: Likelihood of Approval
WSD-0922 is under clinical development by Wayshine Biopharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...
WSD-0922 by Wayshine Biopharma for Metastatic Brain Tumor: Likelihood of Approval
WSD-0922 is under clinical development by Wayshine Biopharma and currently in Phase II for Metastatic Brain Tumor. According to GlobalData,...
WSD-0922 by Wayshine Biopharma for Glioblastoma Multiforme (GBM): Likelihood of Approval
WSD-0922 is under clinical development by Wayshine Biopharma and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
WSD-0922 by Wayshine Biopharma for Anaplastic Astrocytoma: Likelihood of Approval
WSD-0922 is under clinical development by Wayshine Biopharma and currently in Phase II for Anaplastic Astrocytoma. According to GlobalData, Phase...